[The blood pressure lowering effect of bisoprolol, a beta 1-selective receptor blocker--a multicenter study in general practice conditions].

K O Haustein
{"title":"[The blood pressure lowering effect of bisoprolol, a beta 1-selective receptor blocker--a multicenter study in general practice conditions].","authors":"K O Haustein","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The antihypertensive efficacy and compatibility of 5 or 10 mg bisoprolol (Concor) was investigated in patients suffering from essential hypertension (stages I and II according to WHO) in a multicentre, open, non-randomized study. In total, 132 patients were included in the study of 11 outpatient departments. Seventeen patients dropped out because of personal reasons or mistakes of the protocol. If the diastolic blood pressure did not decrease to values < or = 90 mm Hg at the end of the first period of treatment with 5 mg bisoprolol, the dose was doubled to 10 mg within the second period of antihypertensive treatment. At the end of the first period the mean blood pressure decreased from 161.5/104.1 to 141.4/90.8 and after additional 4 weeks to 137.3/87.9 mm Hg. The mean heart rate decreased from 77.5 to 68.8 and 67.7/min, resp. The physicians who treated the patients rated the antihypertensive effect on 80.9% of the patients as good. Undesirable effects of bisoprolol were observed in 20 patients (15.2%). In total, bisoprolol has a good antihypertensive effect. It can be used in most patients as a monotherapeutic drug for treatment of stages I and II of hypertension with daily doses of 5 mg.</p>","PeriodicalId":23901,"journal":{"name":"Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete","volume":"48 10","pages":"476-9"},"PeriodicalIF":0.0000,"publicationDate":"1993-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The antihypertensive efficacy and compatibility of 5 or 10 mg bisoprolol (Concor) was investigated in patients suffering from essential hypertension (stages I and II according to WHO) in a multicentre, open, non-randomized study. In total, 132 patients were included in the study of 11 outpatient departments. Seventeen patients dropped out because of personal reasons or mistakes of the protocol. If the diastolic blood pressure did not decrease to values < or = 90 mm Hg at the end of the first period of treatment with 5 mg bisoprolol, the dose was doubled to 10 mg within the second period of antihypertensive treatment. At the end of the first period the mean blood pressure decreased from 161.5/104.1 to 141.4/90.8 and after additional 4 weeks to 137.3/87.9 mm Hg. The mean heart rate decreased from 77.5 to 68.8 and 67.7/min, resp. The physicians who treated the patients rated the antihypertensive effect on 80.9% of the patients as good. Undesirable effects of bisoprolol were observed in 20 patients (15.2%). In total, bisoprolol has a good antihypertensive effect. It can be used in most patients as a monotherapeutic drug for treatment of stages I and II of hypertension with daily doses of 5 mg.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[一种β - 1选择性受体阻滞剂比索洛尔的降血压作用——一项在一般实践条件下的多中心研究]。
在一项多中心、开放、非随机研究中,研究了5或10 mg比索洛尔(Concor)在原发性高血压(世卫组织规定的I期和II期)患者中的降压疗效和相容性。共纳入11个门诊的132例患者。17例患者因个人原因或方案错误退出。如果在第一期5mg比索洛尔治疗结束时舒张压未降至<或= 90mm Hg,则在第二期降压治疗期间将剂量加倍至10mg。第一期结束时,平均血压从161.5/104.1降至141.4/90.8,4周后降至137.3/87.9 mm Hg,平均心率分别从77.5降至68.8和67.7/min。治疗患者的医生对80.9%的患者的降压效果评价为良好。比索洛尔不良反应20例(15.2%)。综上所述,比索洛尔具有良好的降压效果。它可以在大多数患者中作为单一治疗药物用于治疗I期和II期高血压,每日剂量为5毫克。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Duodenitis]. [Cardiogenic shock]. [In vitro modification of plasma viscosity and erythrocyte aggregation by four plasma substitutes]. [Questions and answers on the epidemiology and etiology of goiter]. [Management of the cold thyroid nodule and thyroid malignancy].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1